Inactive Instrument

Roche Holding Ltd. Share Price Swiss Exchange

Equities

CH0012032048

Pharmaceuticals

End-of-day quote Swiss Exchange
- CHF - Intraday chart for Roche Holding Ltd.

Financials

Sales 2024 * 60.61B 67.56B 5,350B Sales 2025 * 64B 71.34B 5,649B Capitalization 202B 225B 17,796B
Net income 2024 * 13.25B 14.77B 1,170B Net income 2025 * 14.76B 16.45B 1,303B EV / Sales 2024 * 3.56 x
Net Debt 2024 * 14.09B 15.7B 1,244B Net Debt 2025 * 9B 10.03B 795B EV / Sales 2025 * 3.29 x
P/E ratio 2024 *
14.7 x
P/E ratio 2025 *
13.3 x
Employees -
Yield 2024 *
3.92%
Yield 2025 *
4.03%
Free-Float 88.91%
More Fundamentals * Assessed data

Latest transcript on Roche Holding Ltd.

Managers TitleAgeSince
Chief Executive Officer 49 31/12/02
Chairman 57 31/12/07
Director of Finance/CFO 57 31/03/11
Members of the board TitleAgeSince
Director/Board Member 72 02/03/15
Director/Board Member 59 -
Director/Board Member 66 31/12/95
More insiders
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
More about the company